Simon Schafers
Overview
Explore the profile of Simon Schafers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
216
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pajtler K, Sadowski N, Ackermann S, Althoff K, Schonbeck K, Batzke K, et al.
Oncotarget
. 2016 Dec;
8(4):6730-6741.
PMID: 28036269
Polo-like kinase 1 (PLK1) is a serine/threonine kinase that promotes G2/M-phase transition, is expressed in elevated levels in high-risk neuroblastomas and correlates with unfavorable patient outcome. Recently, we and others...
2.
Henssen A, Odersky A, Szymansky A, Seiler M, Althoff K, Beckers A, et al.
Oncotarget
. 2016 Nov;
8(1):430-443.
PMID: 27888795
Neuroblastoma is the most common extracranial tumor in children. Despite aggressive multimodal treatment, high-risk neuroblastoma remains a clinical challenge with survival rates below 50%. Adding targeted drugs to first-line therapy...
3.
Henssen A, Althoff K, Odersky A, Beckers A, Koche R, Speleman F, et al.
Clin Cancer Res
. 2015 Dec;
22(10):2470-81.
PMID: 26631615
Purpose: Targeting BET proteins was previously shown to have specific antitumoral efficacy against MYCN-amplified neuroblastoma. We here assess the therapeutic efficacy of the BET inhibitor, OTX015, in preclinical neuroblastoma models...
4.
Henssen A, Thor T, Odersky A, Heukamp L, El-Hindy N, Beckers A, et al.
Oncotarget
. 2013 Nov;
4(11):2080-95.
PMID: 24231268
Medulloblastoma is the most common malignant brain tumor of childhood, and represents a significant clinical challenge in pediatric oncology, since overall survival currently remains under 70%. Patients with tumors overexpressing...